Siga enters into exclusive license agreement with vanderbilt university for novel poxvirus monoclonal antibodies

New york, oct. 22, 2024 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with vanderbilt university to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mabs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. under the agreement, siga has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mabs globally.
SIGA Ratings Summary
SIGA Quant Ranking